GlassScriptPhysician profile
Baidehi Maiti
NPI 1255580932
$10,568.04
in general payments reported to CMS, 2019-2025
8 companies · $7,945 in 2025
The $7,945 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2022: $122 · 2023: $1,678 · 2024: $811 · 2025: $7,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,725 · Travel and Lodging: $1,731 · Food and Beverage: $908 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44.00 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,725.00 |
| Travel and Lodging | $1,731.24 |
| Food and Beverage | $908.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44.00 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,044.73 | 2024-2025 | Tagrisso, Imfinzi |
| Sobi, INC | $2,510.00 | 2024-2025 | |
| Daiichi Sankyo INC. | $1,553.10 | 2023 | Enhertu |
| Incyte Corporation | $214.80 | 2023-2025 | Jakafi, Jakafi |
| Seagen INC. | $121.80 | 2022 | |
| Tempus Ai, INC | $85.99 | 2024 | |
| Merck Sharp & Dohme LLC | $25.70 | 2025 | Keytruda |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Baidehi Maiti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.